146 related articles for article (PubMed ID: 38611052)
41. A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM].
Gibson D; Vo AH; Lambing H; Bhattacharya P; Tahir P; Chehab FF; Butowski N
BMC Neurol; 2024 Mar; 24(1):103. PubMed ID: 38521933
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
[TBL] [Abstract][Full Text] [Related]
43. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Kavouridis VK; Ligon KL; Wen PY; Iorgulescu JB
J Neurooncol; 2022 May; 158(1):111-116. PubMed ID: 35474499
[TBL] [Abstract][Full Text] [Related]
44. The Impact of
Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
[No Abstract] [Full Text] [Related]
45. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
46. The O
Salah S; Naser W; Jaber O; Saleh Y; Mustafa R; Abuhijlih R; Abuhijla F; Ismaeel T; Yaser S; Sultan I; Mustafa N; Tbakhi A
Rep Pract Oncol Radiother; 2022; 27(5):759-767. PubMed ID: 36523794
[TBL] [Abstract][Full Text] [Related]
47. Prospective Evaluation of
Brighi N; Lamberti G; Andrini E; Mosconi C; Manuzzi L; Donati G; Lisotti A; Campana D
Curr Oncol; 2023 Jan; 30(2):1381-1394. PubMed ID: 36826067
[TBL] [Abstract][Full Text] [Related]
48. DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
Etcheverry A; Aubry M; de Tayrac M; Vauleon E; Boniface R; Guenot F; Saikali S; Hamlat A; Riffaud L; Menei P; Quillien V; Mosser J
BMC Genomics; 2010 Dec; 11():701. PubMed ID: 21156036
[TBL] [Abstract][Full Text] [Related]
49.
Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
[TBL] [Abstract][Full Text] [Related]
50. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K
BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833
[TBL] [Abstract][Full Text] [Related]
51. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
52. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
53. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
[TBL] [Abstract][Full Text] [Related]
54. O
Bobola MS; Alnoor M; Chen JY; Kolstoe DD; Silbergeld DL; Rostomily RC; Blank A; Chamberlain MC; Silber JR
BBA Clin; 2015 Jun; 3():1-10. PubMed ID: 25558448
[TBL] [Abstract][Full Text] [Related]
55. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
57. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
[TBL] [Abstract][Full Text] [Related]
58. MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
[TBL] [Abstract][Full Text] [Related]
59. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
Brandes AA; Franceschi E; Tosoni A; Bartolini S; Bacci A; Agati R; Ghimenton C; Turazzi S; Talacchi A; Skrap M; Marucci G; Volpin L; Morandi L; Pizzolitto S; Gardiman M; Andreoli A; Calbucci F; Ermani M
Neuro Oncol; 2010 Mar; 12(3):283-8. PubMed ID: 20167816
[TBL] [Abstract][Full Text] [Related]
60. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]